CompletedPhase 1

Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer

United StatesStarted 2001-07

Plain-language summary

RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in treating patients who have advanced cancer.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * One of the following diagnoses: * Histologically confirmed advanced primary or metastatic solid tumor, including, but not limited to, the following: * Androgen-independent prostate cancer * Breast cancer * Ovarian cancer * Head and neck cancer * Non-small cell lung cancer * Bladder cancer * Kidney cancer * Diagnosis of lymphoma, multiple myeloma, leukemia, or myelodysplastic syndromes (MDS), including, but not limited to, the following: * Intermediate-grade or follicular non-Hodgkin's lymphoma * Hodgkin's lymphoma * Patients with lymphoma or multiple myeloma must be ineligible for peripheral blood stem cell transplantation * For patients with solid tumors (except prostate cancer): * Disease progression based on development of new lesions or an increase in pre-existing lesions * Biochemical marker increase must not be sole criterion for disease progression * For prostate cancer patients only: * Disease progression based on rising prostate-specific antigen (PSA) values, transaxial imaging, or radionuclide scans * Increase in disease-related symptoms must not be sole manifestation of progression * Patients receiving an antiandrogen as part of first-line hormonal therapy must show disease progression off of the antiandrogen prior to study * Biochemical progression (at least 25% increase over range of values) defined as 1 of the following: * Rising PSA documented by at least 3 consecutive mea…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

Trial details

NCT IDNCT00045006

SponsorMemorial Sloan Kettering Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2005-12

View on ClinicalTrials.gov More Cancer trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.